Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined array key "thumbnail" in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 25
StackHealth / CMS delays Medicare GLP-1 pilot amid insurer skepticism

CMS delays Part D GLP-1 model amid skepticism from insurers

fiercehealthcare - The Trump administration is delaying a voluntary model that aimed to expand access to GLP-1s in Part D after pushback from insurers.

AI Summary: Federal regulators have paused a Medicare Part D pilot to expand coverage for GLP‑1 weight‑loss drugs amid payer skepticism and implementation concerns. The delay reflects worries about cost, program design and insurer buy‑in, forcing policymakers to revisit the model while patients and providers wait for clarity on whether Medicare will shoulder these high‑price therapies.

#obesity #healthcare #pharmaceuticals #drugpricing #weightloss #governmentpolicy #healthcarefinance #diabetes #medicareadvantagenotlisted

CMS pauses Medicare GLP‑1 BALANCE pilot amid insurer pushback

Centers for Medicare & Medicaid Services extends short-term bridge program for GLP-1 obesity drug coverage

4 wks / medicalxpress

CMS delays Part D GLP-1 model amid skepticism from insurers

5 wks / fiercehealthcare

CMS pauses weight-loss BALANCE model for Medicare

5 wks / beckershospitalreview / Elizabeth Casolo

Medicare indefinitely delays pilot plan to cover weight loss drugs

5 wks / endpoints / Max Bayer


Researchers chase GLP‑1 benefits, from gene therapy to Alzheimer’s

Thanks to GLP-1s, Obesity Experts Are Trying to Understand ‘Food Noise’

4 wks / nytimes / Gina Kolata

Semaglutide improves vascular responsiveness to insulin

4 wks / medicalxpress

Weight-loss drugs could tackle Alzheimer's—study

5 wks / medicalxpress

‘It buys patients time’: GLP-1s show early promise in addiction treatment

5 wks / beckershospitalreview / Paige Twenter

Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy

5 wks / endpoints / Ryan Cross

Simple 'gut reset' procedure may prevent weight rebound following GLP-1 discontinuation

5 wks / medicalxpress


Telehealth and clinics scale GLP‑1 access, delivery and monitoring

Beyond the Scale: How Imaging Can Help Determine GLP-1 Efficacy

5 wks / medcitynews / Katie Adams

Telehealth provider Him & Hers adds all FDA-approved GLP-1s to platform

5 wks / fiercehealthcare

Amazon One Medical launches GLP-1 program integrated with primary care

5 wks / fiercehealthcare


All Other Stories

The next phase of the GLP-1 boom

27 days / beckershospitalreview / Paige Twenter

The GLP-1 paradox: Weight loss drugs may lead to stigma

27 days / medicalxpress

GLP-1s overtake oncology drugs in pharma pipelines

27 days / beckershospitalreview / Ella Jeffries

Stopping and restarting certain GLP-1s to lose weight may make the drug less effective

28 days / medicalxpress

Scientists cautiously suggest GLP-1s are safe to use around pregnancy

29 days / medicalxpress

FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on the 503B Bulks List

29 days / oncodaily

GLP-1 Drugs May Cut Risk of Heart Attack, Stroke, and Death by About 13 Percent

4 wks / discovermagazine

Omada signs on with Optum Rx's GLP-1 management program

4 wks / fiercehealthcare

Boston hospital links GLP-1 use to fewer ulcers

4 wks / beckershospitalreview / Ella Jeffries

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial

4 wks / medicalxpress

Court dismisses part of Lilly lawsuit against Empower, some claims can proceed

4 wks / endpoints / Shelby Livingston

FDA seeks to restrict compounding of key GLP-1s

4 wks / beckershospitalreview / Ella Jeffries

Lack of specifics on obesity pill sales hover over Lilly’s first quarter

4 wks / endpoints / Elizabeth Cairns

What to know about GLP-1 drugs for weight loss and health

4 wks / medicalxpress

Early data links Wegovy to risk of 'eye stroke' — here's what to know

4 wks / livescience

GLP-1 semaglutide tied to vision risk: Study

4 wks / beckershospitalreview / Ella Jeffries

One molecule, two effects: A new drug concept to treat obesity and type 2 diabetes

4 wks / medicalxpress

3 barriers to GLP-1 adherence — and how systems are overcoming them

4 wks / beckershospitalreview / Ella Jeffries

The push to expand access to emergency contraception

4 wks / fiercehealthcare / ,

Bariatric surgery is associated with greater long-term heart risk reduction than weight-loss medications

4 wks / medicalxpress

Back to Top / Wednesday, April 22, 2026, 2:23 pm / permalink 22608 / 33 stories in 5 wks /


Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61


Related Stories


Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Medicare unveils new option for covering weight‑loss drugs for seniors / 22 days

Eli Lilly launches Employer Connect to broaden GLP‑1 coverage / 2 months

CVS sues Tennessee over PBM‑pharmacy separation law / 4 days

Optum Rx/Caremark and FTC edge toward settlement in insulin case / 2 months

Novo launches high‑dose Wegovy in US at $399 for self‑pay patients / 7 wks

Lilly’s next‑gen GLP‑1 posts compelling Phase 3 weight and A1C results / 2 months

Trump Administration Secures Lower Obesity Drug Prices / 6 months

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Supplements, Supply Chain, Medicaid, FDA and look for the RSS link.


↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.